Best Oncology Decoded Podcasts (2025)

1
16: Diving Into the Practical Applications of ctDNA in Oncology Care 43:57

Play Pause

12h ago43:57

43:57

In this episode of Oncology Decoded, hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discussed the role that circulating tumor DNA (ctDNA) may play in the monitoring and management of genitourinary cancers as well as other disease types with their colleague, Arnab Basu, MBBS, MPH, FACP. The group began by providing an overview of ctDNA’…

1
🧠💪 From Cravings to Composition: Expanding GLP-1 Frontiers 6:11

16h ago6:11

6:11

🚨 GLP-1 Medicines: Beyond Diabetes! 💉🧠💪 From weight loss to brain health, the future of GLP-1 therapies is unfolding fast! 🌍✨ New agents like retatrutide and MariTide are redefining outcomes in obesity, neurodegeneration, and substance use disorders. 🔬 Oral options, muscle-sparing combos, and triple agonists are here. 🧪 Dive into 15+ FAQs from the …

1
🫀⚖️ Balance After a Meal: The Autonomic Heart Story 6:37

1d ago6:37

6:37

💡 Fresh insights from a randomized crossover trial in people with Type 2 Diabetes (T2D)! 🍽️🚶‍♂️ High-fat 🥑 and high-carb 🍞 meals, with or without a light post-meal walk, showed no adverse effects on cardiac autonomic modulation or ECG intervals. ✅ Heart rate variability held steady, and walking even gave a gentle boost without risk. 🫀 Key Takeaway:…

1
💥 Force, Fibroblasts & 🫀 Failure 3:28

3h ago3:28

3:28

🚨 New Insights in Dilated Cardiomyopathy (DCM)! 🫀 Fibroblasts aren’t just bystanders — they’re mechanical rheostats shaping disease severity. 🧬 This groundbreaking study shows that blocking p38 signaling halts fibrosis, boosts contractility, and may redefine how we treat DCM. 💥 🧠 Think beyond myocytes. Think collective cell behavior. 🧪 Read the ful…

1
🧠 Dysreflexia Decoded & Pressure Rebooted: Circuits, Chaos & Control After Spinal Cord Injury 7:03

2d ago7:03

7:03

🚨 New frontier in #NeuroRehab & #BioelectronicMedicine! Just explored two groundbreaking studies on autonomic dysreflexia and implantable neurostimulation in spinal cord injury (SCI) 🧠💥 ⚡ One reveals the neuronal circuitry driving dangerous BP spikes 🔌 The other shows how epidural stimulation at T11–L1 can restore BP within 2 minutes 💡 Together, th…

1
🫀 Coronary Artery Bypass Blues: Does Lower LDL-C Save the Venous Graft? 4:58

3d ago4:58

4:58

🫀 NEWTON-CABG Trial: Can intensive LDL-C lowering prevent vein graft failure after CABG? 💉 Evolocumab slashed LDL-C by ~50%, but did not improve SVG patency at 2 years. Why? Timing is everything. 🧠 Early SVG failure = thrombosis & hyperplasia—not classic atherosclerosis. LDL-C ≠ magic bullet here. #Cardiology #CABG #LDL #PCSK9 #Evolocumab #CardioTr…

1
From Rest to Reset: 🛌 The Motor Theory & Catecholamine Hypothesis of Sleep 7:11

3d ago7:11

7:11

🧠💤 Why do we sleep? A groundbreaking Neuron article explores this timeless question through a bold new lens: 🛌 The Motor Theory & Catecholamine Hypothesis of Sleep. Instead of a single “sleep center,” 🧬 sleep emerges from distributed motor control circuits regulating both somatic & autonomic activity. And the “why”? 😴 Suppressing dopamine, noradren…

1
Culprit, Complete, or Cautious? 🔧❤️🕰️”: Decoding Revascularisation Timing in STEMI 4:53

4d ago4:53

4:53

🚨 New insights from the Lancet! 🚑 In the OPTION–STEMI trial, immediate multivessel PCI during the index procedure failed to show non-inferiority compared to staged revascularisation in STEMI patients with multivessel disease. 🧠 Key takeaway? Timing matters. ⚠️ Higher risk in those with heart failure (Killip II/III) 💡 Safer strategy: staged PCI for …

1
Dr RR Baliga's Philosophical Discourses: Thomas Aquinas (Italy, 1225–1274 CE) – Summa Theologica 4:28

4d ago4:28

4:28

✨ St. Thomas Aquinas (1225–1274) — Dominican friar, philosopher & theologian — is among the most influential thinkers in Western tradition. 📖 His Summa Theologica shaped Catholic theology, blending Aristotle’s philosophy with Christian faith. 🕊️ Known as the Doctor Angelicus, he championed faith & reason, natural law ⚖️, and virtue ethics 💡— princi…

1
Squeezing the Heart Failure Curve: Risk, Reward, and Vericiguat 📉🧬🔍 7:54

5d ago7:54

7:54

🚨 New Podcast Drop! 🎙️ “VICTOR, Vericiguat, and Victory?” unpacks the Lancet trilogy — the VICTOR trial, pooled analysis, and expert commentary 🧠📊💊. We explore Vericiguat’s evolving role across the heart failure spectrum 💓📉 and what it means for clinical care in HFrEF patients. 📚 Trials discussed: VICTOR, VICTORIA 🎧 Tune in for insights on risk-bas…

1
Episode 351: The Language of Care: Culturally Responsive Breast Health 17:31

2d ago17:31

17:31

During Hispanic Heritage Month, we reflect not only on cultural pride but also on the urgent health challenges facing the Latino community. Breast cancer is the most commonly diagnosed cancer among Latinas, and yet barriers such as language, limited access to care and cultural stigma often prevent women from receiving the support they need. In this…

1
🎨 Art, Health & Hope: Preventing noncommunicable diseases with Creativity 3:17

3d ago3:17

3:17

🎭 Just explored a landmark Nature Medicine review on how the arts can prevent noncommunicable diseases (NCDs) across 27 countries! 🎨 From dance and drama to gardening and storytelling, arts-based interventions improved physical activity, diet, and mental well-being—especially in underserved communities. 📊 A must-read for anyone interested in health…

1
🌍 Obesity, Orals, Outcomes: Rewriting the GLP-1 Script 3:25

7d ago3:25

3:25

💊 Orforglipron: A new era in obesity treatment? In the ATTAIN-1 trial, this oral, nonpeptide GLP-1 receptor agonist delivered up to 11.2% weight loss over 72 weeks—with significant drops in waist circumference, triglycerides, and blood pressure 📉🌡️ 🔥 Nearly 1 in 5 patients lost ≥20% body weight 💡 A promising alternative to injectable therapies Acce…

1
HCM in Two Acts 🎭: Aficamten, Mavacamten & Dueling Data in the Quest to Tame HCM 7:08

7d ago7:08

7:08

🚨 New Podcast Drop! 🎙️ “Myosin, Metrics & Momentum 🧬📈🫀” dives into 3 landmark NEJM articles on Aficamten vs Mavacamten in hypertrophic cardiomyopathy. We decode: 🔹 MAPLE-HCM (obstructive HCM) 🔹 ODYSSEY-HCM (nonobstructive HCM) 🔹 Expert editorial insights on PROs, EF, & trial design 🎯 Learn what matters: peak VO₂ vs PROs, safety signals, and the roa…

1
🧬 Science, Slimming, and Semaglutide Redefining Obesity Treatment—One Tablet at a Time 4:12

8d ago4:12

4:12

💊 New Hope in a Pill for Obesity? The 71-week OASIS 4 trial shows that oral semaglutide 25 mg led to a 13.6% weight loss, improved physical function, and reversed prediabetes in 71% of cases—all without injections. 📉 Effective. 🧬 Metabolically beneficial. 📦 Orally delivered. #ObesityCare #GLP1 #Semaglutide #NEJM #DigitalHealth #Cardiometabolic…

1
🌞 Sun, Skin & Science: The Bright Side of Exposure 3:23

8d ago3:23

3:23

☀️ Walking on Sunshine? Rethinking Our Relationship with the Sun! 🧴🧬 New research—spotlighted in The Economist (Sep 20, 2025)—challenges old assumptions: Could moderate sun exposure reduce cardiovascular mortality? ❤️📉 From nitric oxide to vitamin D, this FAQ explores the science, nuance, and shifting global guidelines. Let’s talk melanin, mortalit…

1
Desmoid Tumors in Focus: Early Recognition, Evolving Therapies, and Nursing-Led Care Strategies 54:51

5d ago54:51

54:51

| Desmoid tumors (DTs) are rare, locally invasive neoplasms that present significant challenges due to their variable presentation, diagnostic delays, and the evolving therapeutic landscape. Oncology nurses and nurse practitioners often lack sufficient training in identifying early signs of DTs, understanding novel systemic therapies like tyrosine …

1
The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations 1:32:45

5d ago1:32:45

1:32:45

| Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face difficulties translating novel and emerging …

1
15: Gathering the Latest Multidisciplinary Care Insights Across World GU 2025 21:58

6d ago21:58

21:58

While attending the 2025 World Conference on Genitourinary Cancers (World GU), Oncology Decoded hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, spoke with various experts and presenters about critical developments that may improve the treatment of patients with different genitourinary malignancies. Bupathi is executive cochair of the Ge…

1
🫀 Cardiogenic Shock Survival: Impella’s Decade-Long Edge 4:46

9d ago4:46

4:46

🚨 Cardiogenic Shock—A Decade Later The DanGer Shock Trial shows that patients with STEMI and shock treated with the Impella CP microaxial flow pump lived 600 more days over 10 years vs standard care alone. 📉 Mortality: 52.5% vs 68.8% (HR 0.70) 🛠️ Despite higher adverse events, the survival benefit endured a full decade. 📊 This changes how we think …

1
Emerging Technologies (Part 3): Microsoft’s Chief Architect for Health on the Saga of Interoperability and AI 48:06

9d ago48:06

48:06

Dr. Josh Mandel says his first love was software. But on a whim, while studying computer science and software engineering at MIT, he took a course that opened his eyes to the world of medicine and genetics. It changed the trajectory of his career away from software – but only temporarily. He entered medical school after earning a bachelor’s degree …

1
💓 Genes, Gradients, and Game-Changers: FAQs on Hypertrophic Cardiomyopathy 7:06

10d ago7:06

7:06

🧠 Hypertrophic Cardiomyopathy — A Masterclass from Eugene Braunwald 🧬 📌 Just published in NEJM (Aug 2025): a sweeping, state-of-the-art review on HCM — from Teare’s first autopsy to myosin inhibitors, AI diagnostics, and gene therapy. 💥 Clinical insights, historical depth, trial data (EXPLORER-HCM, SEQUOIA-HCM, VALOR-HCM), and future-facing advance…

1
🔬 Silence APOC3, Slash Triglycerides, A New Era in Triglyceride Control 4:42

8d ago4:42

4:42

🚨 New NEJM Study on Olezarsen 🚨 In patients with moderate hypertriglyceridemia and elevated cardiovascular risk, monthly subcutaneous olezarsen reduced triglycerides by over 60% at 6 months! 📉💥 ✅ Significant drops in APOC3, VLDL, remnant & non-HDL cholesterol ✅ No rise in LDL-C ✅ Well-tolerated with mild injection-site reactions 🔬 APOC3 inhibition …

1
Dr RR Baliga's Philosophical Discourses: Dogen (Japan, 1200–1253 CE) – Founder of Soto Zen 3:24

8d ago3:24

3:24

🌸 Dōgen Zenji (1200–1253), founder of the Sōtō Zen school in Japan, taught that true practice lies in zazen—“just sitting” 🧘‍♂️—where enlightenment and practice are inseparable. His Shōbōgenzō continues to inspire mindfulness & presence today. ⏳✨ #Zen #MindfulnessBy MasterMedFacts LLC

1
How Microsoft Picks Winning Health Startups with Sally Ann Frank 35:14

8d ago35:14

35:14

What do successful health founders consistently do differently? Sally Ann Frank, Global Lead for Health and Life Sciences at Microsoft for Startups and the author of The Startup Protocol, has mentored startups for decades and noticed patterns. She has the playbook for the repeatable moves that separate billion-dollar health tech companies from the …

1
Episode 350: A Scheduling Mix-Up That Saved My Life 32:51

9d ago32:51

32:51

Naomi’s story is a powerful reminder of how something as simple as a routine mammogram—and even a scheduling mix-up—can change the course of your life. In this conversation, she opens up about her breast cancer journey, the impact it’s had on her career, her family, and her outlook on life, and why she’s passionate about encouraging others to take …

1
14: Elevating Community Oncology Care: Insights From World GU 2025 40:41

12d ago40:41

40:41

Oncology Decoded hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, traveled to the 2025 World Conference on Genitourinary Cancers (World GU) to speak with different experts about important advances and key takeaways related to the care of patients with genitourinary malignancies. Bupathi is executive cochair of the Genitourinary Cancer Re…

1
13: Optimizing Care Planning for Variant Histology Populations at World GU 2025 33:59

13d ago33:59

33:59

In this episode of Oncology Decoded, hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, traveled to the 2025 World Conference on Genitourinary Cancers (World GU) to speak with various experts about key advances in genitourinary oncology. As part of one discussion, Bupathi and Garmezy sat down with Bradley G. Somer, MD, to exchange ideas ab…

1
Part 2: Innovating These NYC Emergency Departments to Address the Mental Health Epidemic 17:46

17d ago17:46

17:46

On this episode of Advances in Care, we return to the high-intensity environment of New York City’s emergency departments with Dr. Angela Mills and Dr. Brenna Farmer. Host Erin Welsh hears from these leaders at NewYork-Presbyterian about how they are implementing innovative strategies to meet the challenges of the behavioral health emergencies epid…

1
Episode 349: Decoding Genetic Testing 30:56

16d ago30:56

30:56

Did you know that in some families with a history of prostate cancer, the women may have an increased risk of breast cancer? People with one or more first-degree relatives (father or brother) who have had prostate cancer may have an increased risk of breast cancer, especially if the prostate cancer was diagnosed at a young age. This also works in r…

1
NSTEMI: 📉 Less Ischemia, Less Reintervention 5:11

19d ago5:11

5:11

🚨 New Evidence in NSTEMI Care! 🫀 The SLIM Trial shows that FFR-guided complete revascularization during the index procedure in patients with NSTEMI and multivessel disease significantly reduces death, MI, stroke, and repeat PCI compared to culprit-only PCI. 🎯 Key win? Fewer revascularizations, better outcomes — physiology beats anatomy again. 📚 Pub…

1
Real-World Rx 💊, Real Results 📉: GLP-1 Agents Slash HFpEF Risk 6:04

23d ago6:04

6:04

💥 Practice-Changing Evidence in HFpEF! 💥 In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% 📉 ⚖️ No meaningful difference between the two agents. 🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies’ expand…

1
The AMALFI AF Screening Trial-📈 Atrial Fibrillation Unmasked: A Modest Win for Mailed Monitors 3:20

23d ago3:20

3:20

📢 Just read the #AMALFI trial in JAMA 📰 — a landmark remote RCT of AF screening using 14-day ECG patches mailed to older adults at stroke risk 📦🫀. At 2.5 years, the patch group had a modestly higher AF detection rate (6.8% vs 5.4%, p=0.03) and increased anticoagulation use 💊🧠. Stroke rates were similar ⚖️. 🎯 Key takeaway: Remote, mail-based AF scre…

1
Part 1: Managing the Complexity of NewYork-Presbyterian’s High Volume Emergency Departments 15:12

23d ago15:12

15:12

On this episode of Advances in Care, host Erin Welsh hears from two emergency department chiefs at NewYork-Presbyterian about how they optimize operations in their uniquely high-intensity, high-volume EDs. Dr. Angela Mills, chief of emergency medicine at NewYork-Presbyterian and Columbia, and Dr. Brenna Farmer, chief of emergency medicine at NewYor…

1
🛑 AFib Gone, OAC Gone? ALONE-AF Challenges Lifelong Therapy 5:14

24d ago5:14

5:14

🚨 New Trial Alert 🚨 Can we safely stop anticoagulation after AF ablation? The ALONE-AF Trial 🫀 suggests yes—in selected patients with no AF recurrence, stopping DOACs reduced major bleeding 🌟 without increasing stroke risk 🧠. 📉 0.3% vs 2.2% for the composite outcome (P = .02) 📍 Carefully monitored, low-risk patients may benefit most. 📝 Editorial: R…

1
🦠💔Bugged After the Heartbreak? Does H. pylori Screening After MI Prevent GI Bleeds? 5:16

24d ago5:16

5:16

🚨 New Findings from the HELP-MI Trial! 🇸🇪🧪 Can routine Helicobacter pylori screening during acute myocardial infarction (MI) hospitalization prevent upper gastrointestinal bleeding (UGIB)? 💉 Over 18,000 patients across 35 Swedish hospitals 📉 Result: No significant reduction in UGIB overall (RR 0.90; P=0.18) 🔍 BUT: Clear benefit in patients with ane…

1
🧬 Risk, Recurrence, Relief: Apixaban’s Edge in VTE 🌡️ Emphasizes the risk stratification, recurrence data, and therapeutic benefit 3:33

25d ago3:33

3:33

🩺 New Insights on Apixaban for VTE! 📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE. 📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding. 🎯 Editorial in NEJM urges a shift from binary labels (“provoked vs unprovoked”) to a patient-centered, risk-adapted approach. 🧠 Art m…

1
Episode 348: Your Healthiest Healthy: Breaking the Code on Breast Cancer 48:42

22d ago48:42

48:42

Today, we are sharing an episode of Your Healthiest Healthy, in which our Honorary Vice Chair, Paula Schneider, made an appearance. In the episode, she discusses her cancer journey, the current landscape, and Paula’s new book, Love Stays Strong, which is out today, September 2.By Susan G. Komen

1
Dr RR Baliga's Philosophical Discourses: Zhu Xi (China, 1130–1200 CE) – Neo-Confucian Philosopher 4:04

22d ago4:04

4:04

🌏 Zhu Xi (1130–1200), a master of Neo-Confucianism, reshaped Chinese philosophy with his focus on rationality, self-cultivation & education. His commentaries on the Four Books guided civil service exams for centuries across East Asia. 📚✨ #Leadership #Philosophy #History #ConfucianismBy MasterMedFacts LLC

1
Gait Speed. Grip Strength. Greater Life. 🦵🤝🌟 A Paradigm Shift in Cardiovascular Recovery for Seniors 5:23

26d ago5:23

5:23

Just read the latest from NEJM? The PIpELINe Trial 🇮🇹 changes how we approach cardiac rehab in older adults post-MI! 🧓❤️ 🎯 A 12-month, multidomain intervention — risk factor control, nutrition 🥗, and Otago-based exercise 👟 — cut CV death/hospitalization from 20.6% → 12.6% (P=0.01)! 📉 Hospitalizations for heart failure dropped 7.1% → 1.5%. No seriou…

1
💊 Block. Beat. Benefit. The Hidden Strength of β-Blockers Post-MI 4:03

27d ago4:03

4:03

🚨 New Meta-Analysis Alert! 💊🫀 Can β-blockers benefit patients post-MI with mildly reduced ejection fraction (LVEF 40–49%)? 📊 An individual patient data meta-analysis (REBOOT, BETAMI, DANBLOCK, CAPITAL-RCT) shows a 25% reduction in the composite outcome of death, MI, or HF with β-blockers vs. control (HR 0.75; p=0.031) — even in the absence of clini…

1
🧠 REBOOTing Beta-Blockers – No Gains ⚖️ After Modern MI 💔 4:59

27d ago4:59

4:59

🚫💊 Should We Rethink Beta-Blockers Post-MI? In the landmark REBOOT trial (NEJM, 2025), beta-blockers failed to reduce mortality, reinfarction, or heart failure hospitalizations in post-MI patients with preserved ejection fraction (>40%). 💡 A modern, pragmatic trial across 109 centers (Spain + Italy 🇪🇸🇮🇹) with 8438 patients — shaking the foundation …

1
Episode 347: Love Stays Strong: Parenting Through Cancer 28:19

24d ago28:19

28:19

We are happy to welcome back the Honorary Vice Chair of Susan G. Komen, Paula Schneider, and today she is also joined by her two daughters Zoe and Chloe. Paula faced a triple-negative breast cancer diagnosis in 2007 – after losing her mother to metastatic breast cancer years before. It goes without saying that Paula’s work is beyond personal. Since…

1
Beta Blockers in MI: Old Drug, New Lens, Possible Win 🔍💥🏥 4:49

28d ago4:49

4:49

🚨 New NEJM Study Alert! 🩺💔 Do beta-blockers still help after a heart attack if there’s no heart failure? 🤔 In the BETAMI–DANBLOCK trial (🇩🇰+🇳🇴, n=5574), beta-blocker therapy in post-MI patients with preserved or mildly reduced LVEF (≥40%) modestly reduced the composite outcome of death or major cardiovascular events 🧠📉 📌 Primary endpoint: 14.2% (BB…

1
🧬 ICDs. K⁺ Boost. Fewer Jolts 6:07

28d ago6:07

6:07

💥 New NEJM Trial Alert! A modest 0.3 mmol/L rise in potassium (via MRA, KCl, or diet) significantly reduced arrhythmias, ICD shocks, and hospitalizations in high-risk ICD patients ⚡🫀 📉 HR 0.76 for the composite endpoint 🔢 NNT = 12.3 over 3.3 years 🍌 Safe, scalable, and globally relevant 👉 Time to rethink “normal” K⁺ levels in cardiology! #Cardiolog…

1
🫀 Foxglove, Frailty, and HFrEF — Digitoxin in Advanced Heart Failure 6:01

29d ago6:01

6:01

🚨 New RCT Alert from the NEJM! Can an old 💊 make a comeback in modern 💓 failure care? 📌 The DIGIT-HF trial showed that digitoxin, a cardiac glycoside with hepatic clearance, reduced the combined endpoint of all-cause death or HF hospitalization in HFrEF patients on contemporary guideline-directed therapy — including ARNI, beta-blockers, MRAs & SGLT…

1
From Sclerosis 🧱 to Stenosis 🚪 to Surgery 🔧 10:04

29d ago10:04

10:04

🚨 Calcific Aortic Valve Stenosis (CAVS): Beyond Wear and Tear 🫀🪨 Once thought to be “degenerative,” CAVS is now recognized as an active disease driven by oxidative stress ⚡, inflammation 🔥, and lipoprotein(a) 🧬. Despite its growing global burden, no drug therapy slows its progression. 🩺 Current management: Surgical (SAVR) or Transcatheter (TAVR) va…

1
💊📉 Mix, Match, and Lower: Predicting BP Drops with Drug Combos 4:44

30d ago4:44

4:44

🚨 New in The Lancet (2025) 🚨 A mega meta-analysis of 484 RCTs (104K+ participants) offers a game-changing approach to hypertension management! 💊📉 Instead of guessing how much BP will drop, now you can predict it—by drug, dose, and combo! 🎯 Like statins for LDL, this study introduces low-, moderate-, and high-intensity BP regimens based on expected …

1
12: Beyond the BEP: A Deep Dive into Testicular Cancer Management 37:44

27d ago37:44

37:44

In this episode of Oncology Decoded, hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, spoke with Nabil Adra, MD, about testicular cancer care. The discussion gave a comprehensive overview of managing germ cell tumors, offering practical pearls for community oncologists. The conversation opened with the initial approach to a patient prese…

1
Partial Hearts. Whole Hope. Lasting Change. 🧩❤️🔬 A Bold Leap Forward in Pediatric Cardiac Surgery 4:43

1M ago4:43

4:43

🧒❤️ Partial Heart Transplant: A Growing Solution for Growing Hearts! 🌱🔬 🚨 Pediatric patients with congenital heart valve disease often face multiple surgeries due to non-living valve grafts that don’t grow. This landmark study from @DukeHealth shows how living valves via partial heart transplant can change the game. 📊 In 19 patients (median age: 97…